ImportRefusal LogoImportRefusal

Paragon Nordic

⚠️ High Risk

FEI: 3005726903 • Vallentuna, Stockholms Lan • SWEDEN

FEI

FEI Number

3005726903

📍

Location

Vallentuna, Stockholms Lan

🇸🇪

Country

SWEDEN
🏢

Address

Fabriksvagen 2, , Vallentuna, Stockholms Lan, Sweden

High Risk

FDA Import Risk Assessment

50.2
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

11
Total Refusals
4
Unique Violations
9/1/2010
Latest Refusal
5/29/2008
Earliest Refusal

Score Breakdown

Violation Severity
83.3×40%
Refusal Volume
40.0×30%
Recency
0.0×20%
Frequency
48.7×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

759×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

162×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

2372×

NO PMA

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the device appears to be a Class III device and does not appear to have in effect an approved application for premarket approval pursuant to Section 515 of the Act, or an exemption pursuant to Section 520(g)(1).

5082×

NO 510(K)

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it is a post 1976 device for which a Section 510(k)application does not appear to have been determined substantially equivalent or otherwise filed.

Refusal History

DateProductViolationsDivision
9/1/2010
79FRODRESSING, WOUND, DRUG
16DIRECTIONS
237NO PMA
508NO 510(K)
New York District Office (NYK-DO)
9/1/2010
79FRODRESSING, WOUND, DRUG
16DIRECTIONS
237NO PMA
508NO 510(K)
New York District Office (NYK-DO)
3/15/2010
64XCQ06SALICYLIC ACID (KERATOLYTIC)
75UNAPPROVED
New York District Office (NYK-DO)
3/15/2010
64XCQ06SALICYLIC ACID (KERATOLYTIC)
75UNAPPROVED
New York District Office (NYK-DO)
9/29/2009
62ICQ24HYDROXYUREA (ANTI-NEOPLASTIC)
75UNAPPROVED
Baltimore District Office (BLT-DO)
5/28/2009
61SDQ99ANTI-ECZEMATIC N.E.C.
75UNAPPROVED
New England District Office (NWE-DO)
5/28/2009
61SDQ99ANTI-ECZEMATIC N.E.C.
75UNAPPROVED
New England District Office (NWE-DO)
6/25/2008
61SDQ99ANTI-ECZEMATIC N.E.C.
75UNAPPROVED
Baltimore District Office (BLT-DO)
6/18/2008
61WDQ28SELENIUM SULFIDE (ANTI-FUNGAL) (NOT ANTIBIOTIC)
75UNAPPROVED
Philadelphia District Office (PHI-DO)
5/29/2008
61SDQ99ANTI-ECZEMATIC N.E.C.
75UNAPPROVED
Philadelphia District Office (PHI-DO)
5/29/2008
61SDQ99ANTI-ECZEMATIC N.E.C.
75UNAPPROVED
Philadelphia District Office (PHI-DO)

Frequently Asked Questions

What is Paragon Nordic's FDA import refusal history?

Paragon Nordic (FEI: 3005726903) has 11 FDA import refusal record(s) in our database, spanning from 5/29/2008 to 9/1/2010.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Paragon Nordic's FEI number is 3005726903.

What types of violations has Paragon Nordic received?

Paragon Nordic has been cited for 4 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Paragon Nordic come from?

All FDA import refusal data for Paragon Nordic is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.